PFS Partners’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$124K Buy
509
+2
+0.4% +$466 0.06% 114
2025
Q4
$105K Buy
507
+4
+0.8% +$791 0.05% 120
2025
Q3
$93.3K Buy
503
+37
+8% +$6.34K 0.04% 119
2025
Q2
$71.1K Buy
466
+4
+0.9% +$615 0.04% 133
2025
Q1
$76.6K Sell
462
-57
-11% -$8.92K 0.04% 120
2024
Q4
$75.1K Sell
519
-484
-48% -$75K 0.04% 116
2024
Q3
$163K Sell
1,003
-147
-13% -$23.4K 0.09% 71
2024
Q2
$168K Sell
1,150
-68
-6% -$10.1K 0.1% 67
2024
Q1
$193K Sell
1,218
-11
-0.9% -$1.75K 0.13% 61
2023
Q4
$193K Buy
1,229
+4
+0.3% +$613 0.13% 54
2023
Q3
$191K Sell
1,225
-97
-7% -$16K 0.17% 41
2023
Q2
$219K Buy
1,322
+125
+10% +$20.2K 0.18% 38
2023
Q1
$185K Buy
1,197
+14
+1% +$2.26K 0.18% 37
2022
Q4
$209K Sell
1,183
-20,355
-95% -$3.51M 0.22% 32
2022
Q3
$3.52M Buy
21,538
+3
+0% +$508 3.8% 11
2022
Q2
$3.82M Buy
21,535
+3
+0% +$535 3.72% 11
2022
Q1
$3.82M Sell
21,532
-139
-0.6% -$23.7K 3.3% 10
2021
Q4
$3.71M Buy
+21,671
New +$3.55M 2.75% 10

Other funds holding JNJ

PFS Partners's JNJ Position: Q1 2026 in Review

PFS Partners increased its Johnson & Johnson (JNJ) stake by 0.39% in Q1 2026, buying an estimated $466 and bringing the position to 509 shares worth $124K. The position accounts for 0.06% of the portfolio, ranked #114.

PFS Partners first reported a position in JNJ in Q4 2021 and has held it in 18 quarters since. The position peaked at $3.82M in Q2 2022. 4,613 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

  • PFS Partners held 509 shares of Johnson & Johnson worth $124K as of Q1 2026.
  • PFS Partners bought 2 Johnson & Johnson shares in Q1 2026, an estimated $466.
  • Johnson & Johnson made up 0.06% of PFS Partners's portfolio in Q1 2026, its #114 holding.
  • PFS Partners first reported a position in Johnson & Johnson in Q4 2021 and has held it in 18 quarters since.
  • PFS Partners's Johnson & Johnson position peaked at $3.82M in Q2 2022.
  • 4,613 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on PFS Partners's 13F filing for Q1 2026, filed 9 Apr 2026.